129779-30-2

Basic information

• Product Name: 1-BOC-3,5-DIMETHYL-PIPERAZINE
• Synonyms: (3R,5S)-3,5-DIMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-3,5-DIMETHYL-PIPERAZINE;1-BOC-CIS-3,5-DIMETHYL-PIPERAZINE;CIS-3,5-DIMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;5-DiMethyl-piperazine-1-carboxylic acid tert-butyl ester;cis-3;1-Piperazinecarboxylic acid, 3,5-diMethyl-, 1,1-diMethylethyl ester, (3R,5S)-;(3R,5S)-rel-tert-Butyl 3,5-diMethylpiperazine-1-carboxylate
• CAS NO: 129779-30-2
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Mol File: 129779-30-2.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 279.7±15.0℃ (760 Torr)
• Flash Point: 123.0±20.4℃
• Appearance: /
• Density: 0.970±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.452
• Storage Temp.: -20°C
• PKA: 8.58±0.60(Predicted)
• CAS DataBase Reference: 1-BOC-3,5-DIMETHYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3,5-DIMETHYL-PIPERAZINE(129779-30-2)
• EPA Substance Registry System: 1-BOC-3,5-DIMETHYL-PIPERAZINE(129779-30-2)

Safety Data

• Hazard Codes: N
• Statements: 36/37/38-50
• Safety Statements: 26-61
• RIDADR: UN3077
• Hazardous Substances Data: 129779-30-2(Hazardous Substances Data)

Usage

Uses

1-Boc-cis-3,5-dimethyl-piperazine is used in the identification of 7-(3-(Piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent, selective and orally bioavailable PI3Kδ inhibitors.

Description

1-BOC-3,5- dimethylpiperazine is a heterocyclic derivative and can be used as pharmaceutical intermediates.

InChI:InChI=1/C11H22N2O2/c1-8-6-13(7-9(2)12-8)10(14)15-11(3,4)5/h8-9,12H,6-7H2,1-5H3/t8-,9+

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 108-49-6 3,5-dimethylpiperazine 
• 75-65-0 tert-butyl alcohol 
• 21655-48-1 cis-2,6-dimethylpiperazine 

Downstream Products

• 198895-89-5 4-benzyl-cis-3,5-dimethylpiperazine1-carboxylic acid tert-butyl ester 
• 1124214-79-4 (3S,5R)-tert-butyl 4-(3-(tert-butylcarbamoyl)benzyl)-3,5-dimethylpiperazine-1-carboxylate 
• 1258305-26-8 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one 
• 1258305-28-0 5-[2-ethoxy-5-((3,4,5-trimethylpiperazin-1-yl)-sulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one citrate 
• 438050-53-4 tert-butyl (3R,5S)-4-(carbonochloridoyl)-3.5-dimethylpiperazine-1-carboxylate 
• 1373010-33-3 (2R,6S)-1-[(4-bromophenyl)methyl]-2,6-dimethylpiperazine 
• 1435953-66-4 (3S,5R)-4-(5-aminothiazolo[5,4-d]pyrimidin-7-yl)-N-(4-methoxyphenyl)-3,5-dimethyl piperazine-1-carboxamide 
• 1124214-75-0 N-tert-Butyl-3-(((2S,6R)-4-(4-(3-cyclobutylureido)benzoyl)-2,6-dimethylpiperazin-1-yl)methyl)benzamide 2,2,2-trifluoroacetate 

Relevant articles and documents

TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION

The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto- temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer

After a high-throughput screening campaign identified thioether 1 as an antagonist of the nuclear androgen receptor, a zone model was developed for structure-activity relationship (SAR) purposes and analogues were synthesized and evaluated in a cell-based luciferase assay. A novel thioether isostere, cyclopropane (1S,2R)-27, showed the desired increased potency and structural properties (stereospecific SAR response, absence of a readily oxidized sulfur atom, low molecular weight, reduced number of flexible bonds and polar surface area, and drug-likeness score) in the prostate-specific antigen luciferase assay in C4-2-PSA-rl cells to qualify as a new lead structure for prostate cancer drug development.